Hyperkalemia

Renal Complications in COVID-19 Described

Publish Date July 24, 2020

Patients hospitalized with COVID-19 who have preexisting kidney conditions are more susceptible to renal complications, a new systematic review and meta-analysis suggest.

Potassium Binder May Increase Sodium Bicarbonate in CKD

Publish Date July 1, 2020

In 3 trials of sodium zirconium cyclosilicate, serum bicarbonate increased regardless of CKD stage.

Patiromer Enables Spironolactone Use in Advanced CKD With Heart Failure

Publish Date June 10, 2020

According to a new analysis of the AMBER study, more heart failure patients treated with patiromer than placebo remained on spironolactone therapy at 12 weeks.

Hyperkalemia Recurrence Risk Rises Along With Number of Episodes

Publish Date June 9, 2020

The risk of hyperkalemia recurrence in patients with chronic kidney disease increases for each hyperkalemia episode a person experiences.

Post-Hyperkalemia Continuation of MRAs Linked to Lower Cardiovascular Risks

Publish Date June 9, 2020

Patients with heart failure who remained on mineralocorticoid receptor antagonists after a hyperkalemia episode had a lower risk for major cardiovascular events than those who stopped taking the medications, a study found.

Potassium Binders Appear Effective for Hyperkalemia in Transplant Recipients

Publish Date June 8, 2020

In 2 small case series of solid-organ transplant recipients, the potassium binders patiromer and sodium zirconium cyclosilicate appeared effective in the short term in managing hyperkalemia.

Plant-Based Diet Not Associated With Serious Hyperkalemia in CKD

Publish Date May 21, 2020

Personalized nutritional counseling appears essential in maintaining a low-protein diet.

Hyperkalemia Management Varies in the US

Publish Date May 21, 2020

No dominant treatment strategy was observed among 11 nephrology practices across the United States.

RAAS Discontinuation in Pediatric Advanced CKD Leads to Kidney Function Decline

Publish Date April 27, 2020

In a propensity score-matched analysis, children who discontinued renin-angiotensin-aldosterone system inhibition (RAASi) had significantly faster eGFR decline compared with those who continued RAASi.

Potassium Binder Dosing Regimen for HD Patients Receives FDA Approval

Publish Date April 27, 2020

In its first label update since sodium zirconium cyclosilicate was approved in 2018, FDA has a dosage regimen specifically to treat hyperkalemia in stable hemodialysis patients.